2 outstanding ASX 200 shares to buy this month according to analysts

Here are a couple of ASX 200 shares that have been rated as buys…

| More on:
a man in a business suite throws his arms open wide above his head and raises his face with his mouth open in celebration in front of a background of an illuminated board tracking stock market movements.

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

There are a lot of options for investors to choose from on the ASX 200. Two that could be in the buy zone right now are listed below.

Here's why analysts rate them as buys:

Aristocrat Leisure Limited (ASX: ALL)

The first ASX 200 share to look at is Aristocrat Leisure. It is one of the world's leading gaming technology companies responsible for many of the most popular pokie machines globally. In addition to this, the company has a growing digital business with a portfolio of hugely popular mobile games such as RAID: Shadow Legends. It is also in the process of acquiring UK listed real money gaming business Playtech for $3.9 billion.

Morgans is a fan of the company and currently has an add rating and $52.00 price target on its shares.

It commented: "We reiterate our ADD rating. In our opinion, the acquisition of PTEC gives ALL the opportunity to get to scale quickly in a market segment forecast to grow at a double-digit rate over the next five years. We expect the strong sector growth to be driven by a North America market growing at a CAGR of close to 50% as more US states liberalise and allow online iGaming and online sports betting."

CSL Limited (ASX: CSL)

Another ASX 200 share that could be in the buy zone is CSL. It is one of the world's leading biotechnology companies, comprising the CSL Behring and Seqirus businesses. Both are leaders in their respective fields – plasma therapies and vaccines.

Citi is bullish on the company, particularly following its Vifor Pharma acquisition announcement, and appears to see the weakness in the CSL share price as a buying opportunity for investors. It has a buy rating and $340.00 price target on its shares.

Citi said: "CSL has announced that the acquisition of Vifor Pharma – it is acquiring the company at CHF165.5 (US$179.25), a ~65% premium to where the stock was trading pre bid discussion and a ~37% premium to the three-month VWAP. We calculate the acquisition to be ~9% accretive to NPATA per share (NPAT before acquisition-related amortization) – a proxy for cash flow."

Motley Fool contributor James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. owns and has recommended CSL Ltd. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on Blue Chip Shares

A happy older couple relax in a hammock together as they think about enjoying life with a passive income stream.
Blue Chip Shares

Buy these quality ASX blue chip shares for a passive income boost

Analysts think these blue chips could be great options for investors searching for passive income.

Read more »

A group of people in suits watch as a man puts his hand up to take the opportunity.
Blue Chip Shares

3 excellent ASX 200 blue chip shares to buy in 2025

Analysts have good things to say about these blue chips.

Read more »

A fit man flexes his muscles, indicating a positive share price movement on the ASX market
Blue Chip Shares

3 strong ASX 200 blue chip stocks to buy with $2,000 in December

These blue chips have been given the thumbs up from analysts.

Read more »

A share market analyst looks at his computer screen in front of him showing ASX share price movements
Blue Chip Shares

Analysts name 3 strong blue chip ASX 200 shares to buy in December

Let's see which blue chips are bring tipped as buys by analysts right now.

Read more »

three businessmen high five each other outside an office building with graphic images of graphs and metrics superimposed on the shot.
Blue Chip Shares

Buy these 3 high-quality ASX 200 blue chip shares in December

Analysts think these high-quality shares are buys right now. Let's see what they are saying.

Read more »

Two people comparing and analysing material.
Blue Chip Shares

Are Woodside or CBA shares a better buy?

Here’s how I’d compare these two major ASX blue chips.

Read more »

A group of young people lined up on a wall are happy looking at their laptops and devices as they invest in the latest trendy stock.
Blue Chip Shares

Why these ASX 200 blue chip shares could generate big returns

Brokers think these shares are could be dirt cheap at current levels.

Read more »

Man sits smiling at a computer showing graphs
Blue Chip Shares

3 ASX shares Australians can buy and hold for the next decade

Analysts think these high quality stocks could be in the buy zone right now.

Read more »